Patents Assigned to HEARTSEED INC.
  • Publication number: 20250043347
    Abstract: Disclosed is a method for evaluating cell differentiation state, including inducing pluripotent stem cells to differentiate into mesodermal cells in a liquid medium by a first differentiation treatment for inducing pluripotent stem cells to differentiate into mesodermal cells and a second differentiation treatment for inducing the mesodermal cells to differentiate into cardiomyocytes; collecting a supernatant of the liquid medium comprising cells induced to differentiate by the second differentiation treatment; and measuring miRNA-3p in miR-1/133a cluster in the supernatant, where the miRNA-3p is at least one selected from a group consisting of miR-1-3p and miR-133a-3p, and the measured value of miRNA-3p is an index of differentiation into cardiomyocytes.
    Type: Application
    Filed: August 2, 2024
    Publication date: February 6, 2025
    Applicants: KEIO UNIVERSITY, HEARTSEED INC., SYSMEX CORPORATION
    Inventors: Shugo TOHYAMA, Otoya SEKINE, Sayaka KANAAMI, Kanako MASUMOTO, Yuki AIHARA
  • Patent number: 10918671
    Abstract: The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species. To solve this problem, the present inventors studied the possibility of constructing cell masses from the purified cardiomyocytes. As a result, they revealed that the stated problem could be solved by providing a method of preparing cell masses of cardiomyocytes derived from pluripotent stem cells, characterized in that cell masses of aggregated cells containing cardiomyocytes that had been differentiated and induced from pluripotent stem cells were dispersed to single cells to thereby obtain purified cardiomyocytes, which were then cultured in a culture medium under serum-free conditions so that they were reaggregated.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: February 16, 2021
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, HEARTSEED INC.
    Inventors: Fumiyuki Hattori, Keiichi Fukuda
  • Patent number: 10544396
    Abstract: An object of the present invention is to provide an agent for improving quality of an iPS cell, a method for producing an iPS cell, an iPS cell produced by such a method for production, and a composition for producing an iPS cell. The method for producing an iPS cell according to the present invention comprises the step of introducing (a) a nuclear reprogramming substance and (b) an H1foo gene or a gene product thereof into a somatic cell. High-quality iPS cells can be produced in greater quantity by introducing not only a nuclear reprogramming substance but also an H1foo gene or a gene product thereof into a somatic cell.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 28, 2020
    Assignee: Heartseed Inc.
    Inventors: Shinsuke Yuasa, Keiichi Fukuda, Akira Kunitomi
  • Publication number: 20180298346
    Abstract: An object of the present invention is to provide an agent for improving quality of an iPS cell, a method for producing an iPS cell, an iPS cell produced by such a method for production, and a composition for producing an iPS cell. The method for producing an iPS cell according to the present invention comprises the step of introducing (a) a nuclear reprogramming substance and (b) an H1foo gene or a gene product thereof into a somatic cell. High-quality iPS cells can be produced in greater quantity by introducing not only a nuclear reprogramming substance but also an H1foo gene or a gene product thereof into a somatic cell.
    Type: Application
    Filed: July 11, 2016
    Publication date: October 18, 2018
    Applicant: Heartseed Inc.
    Inventor: Shinsuke Yuasa
  • Publication number: 20170327787
    Abstract: The present invention has as its object to find out new conditions that make it possible to induce cell death of non-cardiomyocytes or undifferentiated stem cells more completely and to select cardiomyocytes only. In order to achieve this object, there are provided in the present application: a cell culture medium for use in inducing cell death of undifferentiated stem cells, wherein the cell culture medium is free of glutamine in the amino acid profile; and also a method for inducing cell death of non-cardiomyocytes by performing cell culture in said cell culture medium. Further provided in this application are: a cell culture medium for use in selecting cardiomyocytes, wherein the cell culture medium is supplemented with lactate, pyruvate or a fatty acid, free of sugar, and free of glutamine in the amino acid profile; and also a method for selecting cardiomyocytes by culturing a mixture of cardiomyocytes and non-cardiomyocytes in said cell culture medium.
    Type: Application
    Filed: July 16, 2015
    Publication date: November 16, 2017
    Applicant: HEARTSEED INC.
    Inventors: Keiichi FUKUDA, Jun FUJITA, Shugo TOHYAMA